Nkarta remains a high-risk, pre-commercial biotechnology entity entirely dependent on the clinical success of its NKX101 and NKX019 programs to justify its ongoing capital requirements. The firm faces a precarious liquidity position, with cash reserves dwindli...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 10, 2026 | -$0.54-49.9% vs -$0.36 | — vs — |
Q2 2026 May 12, 2026 | -$0.37+5.1% vs -$0.39 | — vs — |
Q2 2026 Mar 25, 2026 | -$0.37-15.6% vs -$0.32 | — vs — |
Q4 2025 Nov 10, 2025 | -$0.29+9.4% vs -$0.32 | — vs — |
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences: September 16, 2026 H.C.
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its selection for three scientific presentations at ACR Convergence 2026 being held November 6-11 in Orlando.
BlackRock Inc. bought a new stake in Nkarta, Inc. (NASDAQ: NKTX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 6,300,212 shares of the company's stock, valued at approximately $17,830,000. BlackRock Inc. owned 8.81% of Nkarta as of its most recent filing
Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Paris, France and New York, USA, July 23, 2026 – Cyllene Therapeutics (“Cyllene Tx”), the global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology, today announced the appointment of Alyssa Levin to its Board of Directors, where she will also serve as Chair of the Audit Committee. The company has also strengthened its leadership team with two key additions. Clara Cambon-Thiebaud joins as Vice President, Regulatory Affairs, based in New York, and Céline Breda as Vice President, Chemistry Manufacturing and Controls (CMC). This leadership team expansion comes as Cyllene Tx advances its lead candidate, EG110A, towards late-stage clinical development for neurogenic bladder-related incontinence.
Benchmark NKTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Nkarta, Inc. (NKTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.88 | $206.05M | -2.04 | — | — | -28.9% | — | |
| $2.53 | $294.89M | -2.20 | -51.24% | -1941.09% | -65.08% | — | |
| $84.00 | $4.1B | -22.22 | — | — | -350.78% | — | |
| $6.11 | $552.18M | -8.73 | -82.52% | -5256.8% | -43.57% | — | |
| $10.19 | $4.55B | -9.35 | 60.6% | -89.09% | -40.51% | — | |
| $0.33 | $42.96M | -0.33 | 266.65% | -1655.35% | -108.72% | — |
Nkarta, Inc. (NKTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Nkarta, Inc. (NKTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Jun 11, 2026·SEC
May 12, 2026·SEC
Get notified when NKTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Nkarta, Inc. (NKTX) stock FAQ — growth, dividends, profitability & financials explained
Nkarta, Inc. (NKTX) reported a net loss of $117.3M for fiscal year 2025.
Nkarta, Inc. (NKTX) has a return on equity (ROE) of -28.9%. Negative ROE indicates the company is unprofitable.
Nkarta, Inc. (NKTX) had negative free cash flow of $93.9M in fiscal year 2025, likely due to heavy capital investments.
